Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher

Natera, Inc.

2024-Q2 EPS reported -$0.86 revenue$781,092,000

Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.
Net loss $37.5M ($0.30 loss per share) vs $110.8M ($0.97) YoY; operating loss $43.9M vs $112.4M.
Processed ~760,300 tests (+23.2%); oncology tests up 50.2% to ~125,400.
Achieved positive cash flow ~$3.3M; FY 2024 revenue guidance raised to $1.49-$1.52B.
Cash and investments $887.1M; outstanding debt $364.0M as of June 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.